Canaccord Genuity Reaffirms Buy Rating for Definium Therapeutics, Inc. (DFTX)
Canaccord Genuity keeps its buy rating for Definium Therapeutics, Inc., setting a $58 price target, a 23.30% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a price target of $58 on June 30, 2026.
- Canaccord Genuity's $58 price target implies 23.30% upside from Definium Therapeutics, Inc.'s ($DFTX) current $47.04 share price.
- Shares of Definium Therapeutics, Inc. traded near $46.55 on Tuesday, with a market cap of approximately $5.97 billion.
- Several insiders, including the CEO and CFO, sold shares on June 25, 2026, as part of planned transactions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Canaccord Genuity reiterated its buy rating for Definium Therapeutics, Inc. (NasdaqGS: DFTX), maintaining a price target of $58. Analyst Sumant Kulkarni affirmed this position as the stock traded near $46.55 on Tuesday.
Canaccord Genuity vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definium Therapeutics, Inc. Stock Up 14.8%
Shares of NasdaqGS:DFTX traded near $46.55 on Tuesday. Definium Therapeutics has a market cap of about $5.97 billion and a forward P/E ratio is not meaningful as the company is not currently profitable. The stock's beta is 2.378, indicating higher volatility compared to the market. Over the past year, the stock has ranged from a low of $6.40 to a high of $47.01, with a 50-day moving average of $24.52 and a 200-day moving average of $17.07. The company maintains a strong liquidity position with a current ratio of 4.692 and a quick ratio of 4.604, while its debt-to-equity ratio stands at 14.622.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Definium Therapeutics has yet to achieve profitability, with an EPS of -$2.50. The company reported zero net margin and a negative return on equity of -94.7%. Investors will be watching the next earnings announcement on July 30, 2026, for further updates on its financial performance.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several planned insider sales occurred on June 25, 2026. CEO Robert Barrow sold 29,208 shares at an average price of $45.03. Chief Medical Officer Daniel Karlin sold 10,035 shares, while Chief Legal Officer Mark Sullivan and Chief Commercial Officer Matthew Wiley sold 13,008 and 2,867 shares, respectively, all at the same average price. Additionally, CFO Brandi Roberts sold 3,013 shares. Earlier, on June 22, 2026, Daniel Karlin bought 100,000 shares, not as part of a planned sale.
Analysts Set New Price Targets
On June 30, 2026, Canaccord Genuity maintained its buy rating for Definium Therapeutics with a $58 price target. This follows a series of similar buy ratings from other firms, including Jones Trading with a $74 target on June 24 and Baird with a $57 target on June 23. The consensus among 15 analysts is a strong buy, with an average target price of $56.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., based in New York, is a biotechnology company focused on developing treatments for brain health disorders. The company's lead products include DT120, in phase 3 trials for anxiety and depressive disorders, and DT402, undergoing phase 2a trials for autism spectrum disorder. Led by CEO Robert Barrow, the company employs 105 people and was formerly known as Mind Medicine (MindMed) Inc. before its rebranding in January 2026.
Bottom Line
Canaccord Genuity's reiterated buy rating on Definium Therapeutics, Inc. reflects continued confidence in the company's potential. The stock's current trading range and analyst targets suggest it remains a focus for investors. As always, it's important to remember that analyst ratings are just one aspect of a broader investment strategy.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.